Efficacy of prophylactic irradiation of internal mammary lymph nodes in breast cancer: a Meta-analysis
10.3760/cma.j.cn113030-20201022-00508
- VernacularTitle:乳腺癌内乳淋巴结预防性照射的 Meta分析
- Author:
Sicong JIA
1
;
Zhikun LIU
;
Jun ZHANG
;
Chenguang ZHAO
;
Longyu ZHU
;
Jie KONG
;
Huina HAN
;
Yuguang SHANG
;
Dongxing SHEN
;
Xuejuan DUAN
Author Information
1. 河北医科大学第四医院/河北省肿瘤医院放疗科，石家庄 050011
- Keywords:
Breast neoplasm/radiotherapy;
Internal mammary lymph node;
Meta-analysis
- From:
Chinese Journal of Radiation Oncology
2021;30(9):903-909
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the effect of prophylactic irradiation of internal mammary lymph nodes in patients with breast cancer in this Meta-analysis.Methods:CNKI, Wanfang Medical network, CBM, PubMed, EMBASE and Web of Science were searched by computer. The controlled clinical studies comparing whether or not internal mammary lymph node irradiation as an intervention were included and the quality of the included literature was evaluated according to Newcastle-Ottawa Scale (NOS). RevMan 5.3 software and Stata 14 software were used for Meta-analysis.Results:A total of 11 original articles were included, and 13 181 patients were included for Meta-analysis. There was no statistically significant difference in the overall survival (OS) between patients with and without internal mammary lymph node irradiation ( P=0.490). The subgroup analysis using the date of treatment and the degree of risk in the enrolled population as criteria showed that 5-year OS was significantly increased after internal mammary area irradiation in high-risk stage Ⅱ-Ⅲ patients (N+ , T 3-T 4 stage) with the date of treatment of after 2000( P=0.003, 0.006). Compared with patients without internal mammary area irradiation, internal mammary irradiation significantly increased the 5-year disease-free survival (DFS)( P<0.001). Conclusion:Under the modern radiotherapy technology, internal mammary lymph node irradiation improves the DFS of patients, and may bring OS benefits to high-risk stage Ⅱ-Ⅲ breast cancer patients (N+ , T 3-T 4 stage).
